Targeted delivery of doxorubicin through conjugation with EGF receptor-binding peptide overcomes drug resistance in human colon cancer cells

British Journal of Pharmacology

Volumn 168, Issue 7, 2013, Pages 1719-1735

  Ai, Shibin ^a   Jia, Tao ^a   Ai, Weilun ^a   Duan, Jianli ^a   Liu, Yongmei ^a   Chen, Jing ^a   Liu, Xin ^a   Yang, Fan ^b   Tian, Yuan ^b   Huang, Zebo ^a  

^a WUHAN UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

doxorubicin; doxorubicin peptide conjugate; drug delivery; drug resistance; EGF receptor

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; DOXORUBICIN; DOXORUBICIN EPIDERMAL GROWTH FACTOR RECEPTOR BINDING PEPTIDE CONJUGATE; MULTIDRUG RESISTANCE PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CELLULAR DISTRIBUTION; COLON CANCER; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TISSUE LEVEL; DRUG UPTAKE; ENDOCYTOSIS; FLUORESCENCE MICROSCOPY; GENE OVEREXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SINGLE DRUG DOSE; SURVIVAL RATE; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENDOCYTOSIS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; P-GLYCOPROTEIN; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS;

EID: 84875189156     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12055     Document Type: Article

References (34)

1. Abbosh PH, Montgomery JS, Starkey JA, Novotny M, Zuhowski EG, Egorin MJ, et al,. (2006). Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Cancer Res 66: 5582-5591.
2. Ai S, Duan J, Liu X, Bock S, Tian Y, Huang Z, (2011). Biological evaluation of a novel doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells. Mol Pharm 8: 375-386.
3. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, et al,. (2009). Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323: 1718-1722.
4. Al-Shawi MK, Polar MK, Omote H, Figler RA, (2003). Transition state analysis of the coupling of drug transport to ATP hydrolysis by P-glycoprotein. J Biol Chem 278: 52629-52640.
5. Aroui S, Brahim M, Kenani A, (2010). Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides in different cell lines: a comparative study. Biochem Biophys Res Commun 391: 419-425.
6. Bajo AM, Schally AV, Halmos G, Nagy A, (2003). Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Clin Cancer Res 9: 3742-3748.
7. Bakos E, Evers R, Calenda G, Tusnády GE, Szakács G, Váradi A, et al,. (2000). Characterization of the amino-terminal regions in the human multidrug resistance protein (MRP1). J Cell Sci 24: 4451-4461.
8. Bidwell GL 3rd, Davis AN, Fokt I, Priebe W, Raucher D, (2007). A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance. Invest New Drugs 25: 313-326.
9. Bild AH, Turkson J, Jove R, (2002). Cytoplasmic transport of Stat3 by receptor-mediated endocytosis. EMBO J 21: 3255-3263.
10. Eckford PD, Sharom FJ, (2009). ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 109: 2989-3011.
11. Gatlik-Landwojtowicz E, Aänismaa P, Seelig A, (2006). Quantification and characterization of P-glycoprotein-substrate interactions. Biochemistry 45: 3020-3032.
12. Gottesman MM, Fojo T, Bates SE, (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58.
13. Grandal MV, Madshus IH, (2008). Epidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosis. J Cell Mol Med 12: 1527-1534.
14. Higgins CF, (2007). Multiple molecular mechanisms for multidrug resistance transporters. Nature 446: 749-757.
15. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
16. Kim D, Lee ES, Park K, Kwon IC, Bae YH, (2008). Doxorubicin loaded pH-sensitive micelle: antitumoral efficacy against ovarian A2780/DOXR tumor. Pharm Res 25: 2074-2082.
17. Lee ES, Na K, Bae YH, (2005). Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release 103: 405-418.
18. Liang JF, Yang VC, (2005). Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity. Bioorg Med Chem Lett 15: 5071-5075.
19. Litman T, Zeuthen T, Svovgaard T, Stein WD, (1997). Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim Biophys Acta 1361: 169-176.
20. Łubgan D, Jõzwiak Z, Grabenbauer GG, Distel LV, (2009). Doxorubicin-transferrin conjugate selectively overcomes multidrug resistance in leukaemia cells. Cell Mol Biol Lett 14: 113-127.
21. Lurje G, Lenz HJ, (2007). EGFR signaling and drug discovery. Oncology 77: 400-410.
22. McGrath J, Drummond G, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
23. Meyer-Losic F, Quinonero J, Dubois V, Alluis B, Dechambre M, Michel M, et al,. (2006). Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (vectocell). J Med Chem 49: 6908-6916.
24. Ogawara K, Un K, Tanaka K, Higaki K, Kimura T, (2009). In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: involvement of cytotoxic effect on vascular endothelial cells. J Control Release 133: 4-10.
25. Ozben T, (2006). Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 580: 2903-2909.
26. Regev R, Yeheskely-Hayon D, Katzir H, Eytan GD, (2005). Transport of anthracyclines and mitoxantrone across membranes by a flip-flop mechanism. Biochem Pharmacol 70: 161-169.
27. Riganti C, Miraglia E, Viarisio D, Costamagna C, Pescarmona G, Ghigo D, et al,. (2005). Nitric oxide reverts the resistance to doxorubicin inhuman colon cancer cells by inhibiting the drug efflux. Cancer Res 65: 516-525.
28. Rottenberg S, Nygren AO, Pajic M, van, Leeuwen FW, van der, Heijden I, van de, Wetering K, et al,. (2007). Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A 104: 12117-12122.
29. Schinkel AH, Jonker JW, (2003). Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55: 3-29.
30. Siarheyeva A, Lopez JJ, Glaubitz C, (2006). Localization of multidrug transporter substrates within model membranes. Biochemistry 45: 6203-6211.
31. Wong HL, Bendayan R, Rauth AM, Xue HY, Babakhanian K, Wu XY, (2006). A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J Pharmacol Exp Ther 317: 1372-1381.
32. Wu W, Luo Y, Sun C, Liu Y, Kuo P, Varga J, et al,. (2006). Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res 66: 970-980.
33. Yamochi T, Aytac U, Sato T, Sato K, Ohnuma K, McKee KS, et al,. (2005). Regulation of p38 phosphorylation and topoisomerase IIα expression in the B-cell lymphoma line Jiyoye by CD26/dipeptidyl peptidase IV is associated with enhanced in vitro and in vivo sensitivity to doxorubicin. Cancer Res 65: 1973-1983.
34. Zhang X, Chibli H, Mielke R, Nadeau J, (2011). Ultrasmall gold-doxorubicin conjugates rapidly kill apoptosis-resistant cancer cells. Bioconjug Chem 22: 235-243.